Related Experiment Video
Updated: May 28, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
[Current management of myelodysplastic syndromes]
1Service d'hématologie clinique, Département de médecine, CHU Sart-Tilman, Université de Liège, Belgique. jo.caers@chu.ulg.ac.be
Abstract:
Treatment of myelodysplastic syndromes (MDS) has improved in recent years with better results of allogeneic stem cell therapy (SCT), the advent of new therapeutic options such as hypomethylating agents and lenalidomide, the introduction of iron chelation therapy and the implication of erythropoietic stimulating agents in the treatment of anemia. In this review, we summarize the different diagnostic and prognostic criteria and outline the different treatment options we have in 2011.
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Mitral Stenosis III: Medical Management
Myocarditis IV: Nursing Management

